Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00937235 · ClinicalTrials.gov registry record · Phase 2
Treatment of Smoking Among Individuals With PTSD
A Phase 2 study of Post Traumatic Stress Disorder and Tobacco Use Disorder, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 2
- Development phase
- 142
- Enrollment target
- 1
- Study location
NCT00937235 is a Phase 2 study of Post Traumatic Stress Disorder and Tobacco Use Disorder that has completed, run by University of Pennsylvania. The registered enrollment target is 142 participants, below the 1,116-participant average among 144 other Post Traumatic Stress Disorder trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00937235, a Phase 2 study of Post Traumatic Stress Disorder and Tobacco Use Disorder, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 142 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will examine the effect of combining prolonged exposure, a cognitive-behavioral treatment program for post-traumatic stress disorder (PTSD) with medication (varenicline) and counseling treatments for smoking cessation. Subjects will be randomly assigned to a 3-month treatment of either: 1) varenicline and smoking cessation counseling alone, or 2) prolonged exposure, varenicline, and smoking cessation counseling. Assessments will be completed at the end of treatment and 6-month follow-up. We hypothesize that, at the end of treatment and at follow-up, abstinence rates and decrease in cigarettes smoked will be greater among participants who receive the combined treatment for both PTSD and smoking.
Conditions Studied
Interventions
- DRUG Varenicline
- BEHAVIORAL Prolonged Exposure
- BEHAVIORAL Medication Management Counseling
Study Locations (1)
Pennsylvania
- University of Pennsylvania School of Medicine, Dept of Psychiatry, Center for Treatment and Study of Anxiety - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2009-01 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00937235
The ClinicalTrials.gov registry entry for NCT00937235 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 142 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,116-participant average among 144 other Post Traumatic Stress Disorder trials with a reported enrollment target (87% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Post Traumatic Stress Disorder appearing as the primary indexed condition, and to 3 interventions - of which Varenicline is the first listed.
NCT00937235 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00937235 about?
NCT00937235 is a clinical study titled "Treatment of Smoking Among Individuals With PTSD". This study will examine the effect of combining prolonged exposure, a cognitive-behavioral treatment program for post-traumatic stress disorder (PTSD) with medication (varenicline) and counseling treatments for smoking cessation. Subjects will be randomly assigned to a 3-month treatment of either: 1...
What is the current status of trial NCT00937235?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 142 participants. The study started on 2009-01. Estimated completion is 2015-12.
What conditions does trial NCT00937235 study?
This clinical trial studies the following conditions: Post Traumatic Stress Disorder, Tobacco Use Disorder, Nicotine Dependence, Cigarette Smoking.
What interventions are being tested in trial NCT00937235?
The interventions under investigation include: Varenicline (DRUG), Prolonged Exposure (BEHAVIORAL), Medication Management Counseling (BEHAVIORAL).
Who is sponsoring clinical trial NCT00937235?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00937235 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Post Traumatic Stress Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Department of Defense PTSD Adaptive Platform Trial - Intervention A - Fluoxetine
RECRUITING · Phase 2
-
Facilitation of Extinction Retention and Reconsolidation Blockade by IV Allopregnanolone in PTSD.
RECRUITING · Phase 2
-
Facilitation of Extinction Retention and Reconsolidation Blockade in PTSD
RECRUITING · Phase 2
-
Department of Defense PTSD Adaptive Platform Trial - Master Protocol
RECRUITING · Phase 2
-
MDMA for AUD/PTSD Comorbidity
RECRUITING · Phase 2
-
Enhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol (R33)
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.